Tri-Service General Hospital Joins Taiwan Clinical Trial Center Alliance (TACTC), Creating a New Milestone for Biomedical R&D in the Asia-Pacific Region
Update Date：2026/01/05，
Views：141
In December 2025, Taiwan's clinical research and development (R&D) entered a transformative milestone. Under the guidance of the Ministry of Health and Welfare, the Taiwan Clinical Trial Center Alliance (TACTC), consisting of 32 top medical centers across Taiwan, was officially launched. As the only national-level military medical center in Taiwan, Tri-Service General Hospital was invited to join this biotech "national team" due to its strong foundation in military medicine and outstanding translational research capabilities. This partnership not only represents an integration of administrative resources but also symbolizes the hospital's key ability to lead the Asia-Pacific region in improving the speed, quality, and innovation of clinical trials.
Highlight 1: Process Reengineering to Build an Efficient Administrative Accelerator
For many years, administrative reviews have been a major bottleneck in biomedical R&D. Upon joining the alliance, Tri-Service General Hospital's first priority is to promote the optimization of the "Collaborative Institutional Review Board (cIRB)" process. Through the implementation of a "single-window" mechanism and the standardization of public contracts, the hospital plans to reduce the clinical trial startup time from six months to just a few weeks. This "administrative accelerator" will not only enhance Tri-Service General Hospital's international competitiveness but also create a transparent, efficient, and predictable R&D environment, ensuring that high-end medical research stays in sync with global biomedical trends.
Highlight 2: Focusing on Early-Stage R&D, Setting Up for Regenerative Medicine
In the TACTC strategic layout, Tri-Service General Hospital has been tasked with strengthening "early-stage new drug development and Phase I clinical trials." The hospital's Clinical Trial Center currently boasts 50 dedicated beds and has passed numerous audits by the Ministry of Health and Welfare, demonstrating its high standards in patient care. In line with the implementation of the "Regenerative Medicine Dual Laws," the hospital has proactively formed strategic alliances with biotech giants that meet international standards (such as PIC/S GMP, GTP, etc.) for cell preparation. This collaboration aims to seamlessly connect "Bench to Bedside" in regenerative medicine, striving to become the global hub for precision medical R&D.
Highlight 3: Expanding MRCT Strategy, Gaining Insight into Asia's Genetic Landscape
Building on the "3+1 Clinical Trial Alliance" military-civilian cooperation experience, Tri-Service General Hospital continues to expand its multi-country, multi-center clinical trial (MRCT) strategy. Beyond accelerating the market approval process for new drugs, the core value of this initiative lies in capturing genetic data and pharmacokinetic parameters unique to Asian populations. This is crucial for enhancing the strategic depth of precision medicine R&D, holding irreplaceable academic and clinical significance.
Conclusion: Professional Synergy to Save Lives
Hospital Director Major General Chai Yi-Ting emphasized that joining TACTC is a commitment to fulfilling its professional mission. When clinical expertise and administrative efficiency resonate together, not only will Taiwan be propelled to become a key R&D hub in the Asia-Pacific, but it will also provide cutting-edge medical opportunities to patients with complex conditions, giving them a life-saving advantage. This will showcase the powerful research and development momentum of Tri-Service General Hospital to the world.
